IOVANCE BIOTHERAPEUTICS FILES 8-K
Ticker: IOVA · Form: 8-K · Filed: Jun 28, 2024 · CIK: 1425205
| Field | Detail |
|---|---|
| Company | Iovance Biotherapeutics, Inc. (IOVA) |
| Form Type | 8-K |
| Filed Date | Jun 28, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.000041666 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K
Related Tickers: IOVA
TL;DR
IOVA filed an 8-K for financial statements/exhibits. No major news yet.
AI Summary
On June 28, 2024, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating updates or disclosures related to the company's financial health and operations. No specific material events or transactions were detailed in the provided excerpt.
Why It Matters
This filing provides an update on IOVANCE BIOTHERAPEUTICS, INC.'s financial statements and exhibits, which can offer insights into the company's financial position and operational activities.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any immediate material adverse events.
Key Players & Entities
- IOVANCE BIOTHERAPEUTICS, INC. (company) — Registrant
- June 28, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-36860 (identifier) — Commission File Number
- 75-3254381 (identifier) — I.R.S. Employer Identification No.
- 825 Industrial Road , Suite 400 (address) — Business Address
- San Carlos (location) — City
FAQ
What is the primary purpose of this 8-K filing by IOVANCE BIOTHERAPEUTICS, INC.?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of June 28, 2024.
When was this 8-K report filed?
This 8-K report was filed on June 28, 2024.
In which state is IOVANCE BIOTHERAPEUTICS, INC. incorporated?
IOVANCE BIOTHERAPEUTICS, INC. is incorporated in Delaware.
What is the Commission File Number for IOVANCE BIOTHERAPEUTICS, INC.?
The Commission File Number for IOVANCE BIOTHERAPEUTICS, INC. is 001-36860.
What is the business address listed for IOVANCE BIOTHERAPEUTICS, INC.?
The business address listed is 825 Industrial Road, Suite 400, San Carlos, CA 94070.
Filing Stats: 432 words · 2 min read · ~1 pages · Grade level 9 · Accepted 2024-06-28 07:30:48
Key Financial Figures
- $0.000041666 — h registered Common stock, par value $0.000041666 per value IOVA The Nasdaq Stock Marke
Filing Documents
- tm2418485d1_8k.htm (8-K) — 26KB
- tm2418485d1_ex99-1.htm (EX-99.1) — 15KB
- tm2418485d1_ex99-1img001.jpg (GRAPHIC) — 4KB
- 0001104659-24-075997.txt ( ) — 221KB
- iova-20240628.xsd (EX-101.SCH) — 3KB
- iova-20240628_lab.xml (EX-101.LAB) — 33KB
- iova-20240628_pre.xml (EX-101.PRE) — 22KB
- tm2418485d1_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On June 28, 2024, Iovance Biotherapeutics, Inc. issued a press release announcing submission of a marketing authorization application to the European Medicines Agency for lifileucel in advanced melanoma. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
01. Financial
Item 9.01. Financial (d) Exhibits. Exhibit Number Description 99.1 Press Release dated June 28, 2024. 104 Cover Page Interactive Data File, formatted in Inline XBRL and included as Exhibit 101
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Iovance Biotherapeutics, Inc. Dated: June 28, 2024 By: /s/ Frederick G. Vogt Name: Frederick G. Vogt, Ph.D., J.D. Title: Interim CEO and President, and General Counsel